P. Folegatti

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

A. Lawrie, A. Hill, S. Gilbert, 2019, Vaccines.

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

S. Faust, A. Lawrie, L. Coughlan, 2018, EBioMedicine.

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Mohammed J. F. Alenazi, H. Balkhy, S. Gilbert, 2021, The Lancet Microbe.

A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection

C. Drakeley, W. Monteiro, A. Siqueira, 2017, Malaria Journal.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

P. Klenerman, A. Winston, G. Screaton, 2022, JCI insight.

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

A. Pollard, P. Aley, M. Voysey, 2022, eBioMedicine.

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020, The Lancet. Infectious diseases.

Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020 .

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

P. Folegatti, D. Jenkin, Susan J. Morris, 2022, Vaccine.

Vaccines against Ebola virus.

A. Hill, P. Folegatti, N. Venkatraman, 2017, Vaccine.

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol

C. Butler, Ly-Mee Yu, A. Hill, 2019, F1000Research.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

P. Klenerman, A. Winston, G. Screaton, 2021 .

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.

S. Madhi, K. Dheda, P. Aley, 2020 .

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics

A. Lawrie, W. Nahrendorf, S. Draper, 2022, Frontiers in Immunology.

Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR

M. Shankar-Hari, P. Simmonds, D. Bonsall, 2022, Journal of clinical microbiology.

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

Ly-Mee Yu, A. Lawrie, M. Shanyinde, 2021, Vaccines.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Young Chan Kim, A. Lawrie, A. Hill, 2021, Nature Communications.

Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction

M. Shankar-Hari, P. Simmonds, D. Bonsall, 2021, medRxiv.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

D. Bonsall, V. Libri, J. Vekemans, 2021 .

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

P. Klenerman, A. Winston, G. Screaton, 2021, The Lancet HIV.

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

G. Alter, M. White, S. Faust, 2021, Med.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers

S. Sirima, B. Angus, A. Lawrie, 2019 .

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

G. Screaton, P. Aley, B. Angus, 2021, SSRN Electronic Journal.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

A. Pollard, P. Aley, M. Voysey, 2023, Clinical and experimental immunology.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

P. Klenerman, A. Winston, A. Goodman, 2021, SSRN Electronic Journal.

HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT

J. Baum, A. Blagborough, S. Faust, 2017 .

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

A. Lawrie, A. Hill, J. Hermon-Taylor, 2019, Vaccines.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

A. Pollard, P. Aley, B. Angus, 2020, Lancet.

C. Butler, Ly-Mee Yu, A. Hill, 2019, F1000Research.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

A. Pollard, P. Aley, B. Angus, 2020, Lancet.